These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 2862253)

  • 1. Disposition of HI-6 oxime in rats after intravenous and intramuscular administration.
    Simons KJ; Briggs CJ
    J Pharm Pharmacol; 1985 May; 37(5):367-9. PubMed ID: 2862253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HI-6 pharmacokinetics in rabbits after intravenous and intramuscular administration.
    Lukey BJ; Woodard CL; Clark CR; McCluskey MP
    J Pharm Pharmacol; 1992 Aug; 44(8):690-2. PubMed ID: 1359099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
    Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
    Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of HI-6 in beagle dogs.
    Simons KJ; Briggs CJ
    Biopharm Drug Dispos; 1983; 4(4):375-88. PubMed ID: 6661515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous application of HI-6 salts (dichloride and dimethansulphonate) in pigs: comparison with pharmacokinetics profile after intramuscular administration.
    Zdarova Karasova J; Zemek F; Kunes M; Kvetina J; Chladek J; Jun D; Bures J; Tachecí I; Kuca K
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():74-8. PubMed ID: 24362096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and equivalent systemic bioavailability of the antidotes HI-6 and dicobalt edetate via the intraosseous and intravenous routes.
    Hill SL; Thomas SH; Flecknell PA; Thomas AA; Morris CM; Henderson D; Dunn M; Blain PG
    Emerg Med J; 2015 Aug; 32(8):626-31. PubMed ID: 25414476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors.
    Spöhrer U; Thiermann H; Klimmek R; Eyer P
    Arch Toxicol; 1994; 68(8):480-9. PubMed ID: 7802588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimedoxime and HI-6: kinetic comparison after intravenous administration to mice.
    Milic B; Maksimovic M; Nedelijkovic M
    Pharmacol Toxicol; 1996 Apr; 78(4):269-72. PubMed ID: 8861786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and toxicity of the oxime HGG 12 in dogs.
    Klimmek R; Eyer P
    Arch Toxicol; 1985 Sep; 57(4):237-42. PubMed ID: 4091648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine.
    Clement JG; Bailey DG; Madill HD; Tran LT; Spence JD
    Biopharm Drug Dispos; 1995 Jul; 16(5):415-25. PubMed ID: 8527690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral kinetics and bioavailability of the cholinesterase reactivator HI-6 after administration of 2 different formulations of tablets to dogs.
    Maksimović M; Jovanović D; Kovacević V; Bokonjić D
    Toxicol Lett; 1987 Nov; 39(1):85-91. PubMed ID: 3672559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector.
    Nyberg AG; Cassel G; Jeneskog T; Karlsson L; Larsson R; Lundström M; Palmer L; Persson SA
    Biopharm Drug Dispos; 1995 Nov; 16(8):635-51. PubMed ID: 8573684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7.
    Thiermann H; Radtke M; Spöhrer U; Klimmek R; Eyer P
    Arch Toxicol; 1996; 70(5):293-9. PubMed ID: 8852700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K727, K733) with the oxime HI-6 and obidoxime in sarin-poisoned rats and mice.
    Kassa J; Sepsova V; Matouskova L; Horova A; Musilek K
    Toxicol Mech Methods; 2015 Mar; 25(3):229-33. PubMed ID: 25894563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice.
    Kassa J; Karasova J; Musilek K; Kuca K
    Toxicology; 2008 Jan; 243(3):311-6. PubMed ID: 18054821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HI-6 and 2-PAM in sheep: pharmacokinetics and effects on muscle tissue following intramuscular injection.
    Moore DH; Hayward IJ; Tucker FS; Lukey B
    Biopharm Drug Dispos; 1991 Apr; 12(3):223-32. PubMed ID: 2059672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic profile in blood and brain of the cholinesterase reactivating oxime HI-6 after intravenous administration to the rat.
    Ligtenstein DA; Kossen SP
    Toxicol Appl Pharmacol; 1983 Nov; 71(2):177-83. PubMed ID: 6636183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
    Soback S; Ziv G
    Res Vet Sci; 1989 Sep; 47(2):158-63. PubMed ID: 2799072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies on the metabolic fate of isepamicin sulfate (HAPA-B). I. Absorption, distribution, metabolism and excretion in rats].
    Suzuki T; Serizawa K; Somiya Y; Shirai M; Endo S; Morishita M
    Jpn J Antibiot; 1987 Jan; 40(1):188-201. PubMed ID: 3586328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of cyanide after i.v. administration of the oxime HI 6 to dogs.
    Eyer P; Kawan A; Ladstetter B
    Arch Toxicol; 1987; 61(1):63-9. PubMed ID: 3439876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.